Morning Overview on MSN
The FDA approved a lower-dose contrast agent to cut patients’ exposure during MRI scans
Patients who need repeated MRI scans with contrast dye could soon receive a fraction of the gadolinium they currently get.
The FDA has approved Bayer’s Ambelvist (gadoquatrane), the lowest-dose macrocyclic GBCA for adult and pediatric contrast-enhanced CNS and body MRI exams.
Hosted on MSN
The Risks and Benefits of MRI Contrast Dye
You are at the healthcare provider’s office, and they tell you that you need an MRI scan with contrast dye. You might feel a little nervous about having chemicals put into your body. You might wonder, ...
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast agents during MRI scans. Emerging research suggests gadolinium-based contrast ...
New MRI technology aims to advance neuroimaging and biomarker research CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS,i a ...
Whole-body MRI (WB-MRI) may improve ALS diagnostic certainty. WB-MRI assesses muscle swelling (edema) as a marker for lower ...
The FDA has approved Ambelvist, a macrocyclic gadolinium-based option for contrast-enhanced MRI, now the lowest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results